What Ojemda’s JCA reveals about new era of clinical HTA in Europe
The first published joint clinical assessment (JCA) hands the innovative pharmaceutical industry a working template for a process that will…
Pricing and Market Access
US patent infringement investigation targets German drug price control measures
CDA data reveals trends on drug approvals and reimbursements in Canada
Healthcare cost inflation is back in the headlines
Japan’s FY26 price revision expands G1 repricing and drives price reduction
MFN changing the rules of the game for the Nordic countries
The Most Favored Nation Policy: early insights into Europe’s response
GlobalData’s key thoughts from World EPA Congress 2026
